Novo Nordisk A/S vs Taiwan Semiconductor Manufacturing Company: Strategic Comparison

This in-depth comparison examines Novo Nordisk A/S and Taiwan Semiconductor Manufacturing Company across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Novo Nordisk A/S on its own, evaluating Taiwan Semiconductor Manufacturing Company, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Novo Nordisk A/S and Taiwan Semiconductor Manufacturing Company is widest.

On the headline numbers, Novo Nordisk A/S reports annual revenue of $42.7B against $90.0B for Taiwan Semiconductor Manufacturing Company, while their respective market capitalizations stand at $550.0B and $900.0B. Novo Nordisk A/S is headquartered in Denmark and Taiwan Semiconductor Manufacturing Company operates from Taiwan, and those different home markets shape how each company competes.

Novo Nordisk A/S: A single molecule generated 215.2 billion Danish Krone in FY2024 sales. Semaglutide — marketed as Ozempic for diabetes and Wegovy for obesity — is the most commercially successful pharmaceutical product of the current decade and possibly the most consequential medicine introduced since statins. Novo Nordisk generated 290.42 billion DKK (approximately $42.7 billion) in total FY2024 revenue, and 74% of that revenue came from one chemical compound first synthesized by the company's researchers. That concentration is simultaneously the source of extraordinary financial performance and the central strategic risk of the entire enterprise. Novo Nordisk's origins in 1923 and 1925 as two separate Danish insulin laboratories trace back to August Krogh, a Danish Nobel laureate who learned of insulin's discovery in Canada in 1922 and obtained a license to manufacture it in Scandinavia. For eight decades, the company operated as a high-quality but relatively constrained insulin manufacturer competing in a global market where Eli Lilly, Sanofi, and others were similarly positioned. The incretin class of drugs — GLP-1 receptor agonists that stimulate insulin secretion while suppressing appetite — changed everything. Semaglutide, the optimized GLP-1 agonist that Novo Nordisk developed over fifteen years of research, proved effective not just for blood sugar control but for substantial, sustained weight loss. The company operates from Bagsværd, Denmark, a suburb of Copenhagen where the research and manufacturing infrastructure that produced semaglutide was built over decades. The 77,900 employees across global manufacturing facilities cannot produce Wegovy and Ozempic fast enough to meet demand — a problem that is simultaneously evidence of unprecedented commercial success and a constraint on revenue growth. Novo Holdings, the controlling shareholder, acquired Catalent in 2024 for $16.5 billion specifically to secure additional manufacturing capacity. CEO Lars Fruergaard Jørgensen has been managing a company that grew from $24.8 billion in FY2022 revenue to $42.7 billion in FY2024 — 72% growth in two years — while simultaneously trying to build the manufacturing infrastructure to support a demand trajectory that no pharmaceutical company in history had previously experienced.

Taiwan Semiconductor Manufacturing Company: TSMC manufactures roughly 90% of the world's most advanced semiconductors on an island 110 miles from the Chinese mainland. That geographic concentration — with no historical precedent in modern industrial infrastructure — makes Taiwan Semiconductor the single most strategically important manufacturing facility on Earth, a position that generates both $90 billion in annual revenue and a geopolitical risk profile that no diversification strategy can fully eliminate. The $900 billion market capitalization on $90 billion in fiscal 2024 revenue implies a ten-times revenue multiple. That premium reflects the company's position as the only entity capable of manufacturing the most advanced chips that power artificial intelligence systems, the latest generation of smartphone processors, and military electronics. ASML's High-NA EUV lithography machines — which cost approximately $380 million each and are required for post-2nm process nodes — are allocated to TSMC first, as ASML's largest customer. No competitor receives those machines before TSMC. The foundry model that Morris Chang invented in 1987 solved an industrial coordination problem that the semiconductor industry did not know it had. Before TSMC, every chip designer had to either build its own fabrication facility — an increasingly expensive proposition — or license manufacturing capacity from an integrated device manufacturer that was also a direct competitor. Chang separated design from manufacturing permanently, enabling an entire generation of fabless companies to emerge: Qualcomm, NVIDIA, AMD, Apple Silicon. Revenue has grown from $67.6 billion in fiscal 2023 to $90 billion in fiscal 2024 — a $22.4 billion increase in a single year driven primarily by AI chip demand. NVIDIA's H100 and successor GPU architectures are manufactured at TSMC, and the demand for those chips from hyperscale cloud providers has been running above TSMC's available capacity since mid-2023. The CoWoS advanced packaging technology became a specific bottleneck in 2023, prompting TSMC to triple capacity through 2024 to address approximately 18 months of backlogged demand.

Novo Nordisk A/S and Taiwan Semiconductor Manufacturing Company pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Novo Nordisk A/S and Taiwan Semiconductor Manufacturing Company.

Novo Nordisk A/S business model: For the first 80 years of its existence, the organization operated primarily as a low-margin, high-volume manufacturer of animal-derived and later recombinant human insulins, competing in a crowded market where pricing was heavily regulated by European national health systems and US government procurement contracts. The pricing power inherent in the innovative pharma model allows Novo Nordisk to charge premium list prices in the US market, which accounts for approximately 65% of total global sales. However, this pricing power is heavily distorted by the US pharmacy benefit manager (PBM) system. Novo Nordisk's Insulin glargine (Levemir) and Insulin aspart (NovoLog) are locked in a price war with Sanofi's Lantus and Eli Lilly's Humalog, a battle that has been exacerbated by the introduction of interchangeable biosimilars and the aggressive pricing tactics of the big three PBMs in the US. This strategy of identifying unmet medical needs in complex, chronic diseases and developing targeted therapies to address them is a core component of Novo Nordisk's competitive strategy, allowing the company to command premium pricing and achieve high margins despite the intense competitive pressure in the broader metabolic disease market. While legacy insulin sales declined by 4% due to biosimilar competition and VBP pricing pressure in China, the combined sales of Ozempic (146.9 billion DKK), Wegovy (68.2 billion DKK), and Rybelsus (2.8 billion DKK) demonstrated that the next generation of incretin therapies is achieving commercial scale faster than anticipated. The US market remains the most profitable region, contributing approximately 65% of total revenue but an even higher percentage of operating profit due to the significantly higher pricing power for innovative biologics in the United States compared to Europe and Asia. Concurrently, the company is navigating intense structural pricing pressure in the US, the world's most profitable pharmaceutical market. While the FDA has recently cracked down on these practices, the existence of a parallel, low-cost supply chain has permanently altered patient expectations regarding the pricing of GLP-1 therapies, making it increasingly difficult for Novo Nordisk to maintain its premium list prices without facing intense public and political backlash. The company's deep integration with academic medical centers through its clinical trial network creates a feedback loop of real-world data that accelerates regulatory approvals and label expansions, further entrenching its dominance in the therapeutic area. The company must also navigate the complex and evolving pricing and reimbursement landscape, particularly in the US where the implementation of the Inflation Reduction Act is expected to put significant downward pressure on drug prices.

Taiwan Semiconductor Manufacturing Company business model: TSMC's gross margins reached approximately 53 to 54 percent in the second half of 2024, figures that reflect not just manufacturing efficiency but genuine pricing power — a rare commodity in any industrial business. Every dollar of revenue TSMC earns comes from charging customers a fee to manufacture chips according to those customers' proprietary designs. The pricing structure in semiconductor foundry is fundamentally different from other contract manufacturing industries. TSMC charges customers on a per-wafer basis, with prices increasing dramatically as process nodes advance. With the highest volumes of advanced wafer production in the world, TSMC can amortize equipment and process development costs across more units than any competitor, achieving lower per-unit costs at equivalent pricing. These process advances keep TSMC at the forefront of manufacturing technology and maintain the pricing premium associated with leading-edge nodes. The funding structure was itself a deliberate statement of commitment: Taiwan's government through ITRI contributed approximately 48 percent, Dutch semiconductor company Philips contributed 27.5 percent (bringing technical credibility and access to process technology licenses), and the remainder came from private Taiwanese investors.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Novo Nordisk A/S stack up against those of Taiwan Semiconductor Manufacturing Company.

Novo Nordisk A/S competitive advantage: The execution of this strategy requires flawless commercial execution and unprecedented manufacturing scale, capabilities that were severely tested in 2023 when the FDA issued warnings to compounding pharmacies that were illegally producing unapproved versions of semaglutide to bypass the official supply shortages. The successful completion of these trials has established semaglutide as a foundational therapy for cardiorenal protection, a competitive advantage that is extremely difficult for new entrants to replicate without conducting their own multi-year, multi-billion dollar outcomes trials. This specific molecular architecture is protected by a dense thicket of composition-of-matter, formulation, and method-of-use patents that do not expire until the mid-2030s, creating a legal barrier to entry that is virtually impossible to close quickly. This clinical data package, encompassing over 100,000 patient-years of exposure across the STEP, SUSTAIN, PIONEER, and SELECT trial programs, represents a competitive advantage that is rooted in deep scientific expertise, massive capital barriers, and regulatory exclusivity. The manufacturing moat is equally formidable. Novo Nordisk operates the largest peptide fermentation facilities in the world, located in Kalundborg, Denmark, which are specifically designed to handle the complex biological processes required to produce semaglutide at commercial scale. The sheer cost and regulatory complexity of building and operating these facilities deter all but the most well-capitalized competitors from attempting to enter the GLP-1 space, giving Novo Nordisk a significant cost and scale advantage that will be difficult to replicate. This regulatory expertise, combined with its manufacturing scale and clinical data dominance, creates a comprehensive competitive advantage that positions Novo Nordisk as the undisputed leader in the rapidly evolving field of incretin therapies. The commercial infrastructure required to support this advantage is equally specialized. If these trials are successful, Novo Nordisk could potentially launch semaglutide for MASH by 2027, establishing another first-mover advantage in a completely new therapeutic area and creating a multi-billion dollar revenue stream that would significantly diversify the company's portfolio. Novo Nordisk has established a dedicated AI and data science hub in Copenhagen, which is focused on developing machine learning algorithms to analyze large-scale biological datasets, identify novel peptide targets, and optimize the design of clinical trials.

Taiwan Semiconductor Manufacturing Company competitive advantage: The structural challenge Intel faces is that building competitive foundry capability requires the same decades of manufacturing culture, process optimization, and ecosystem development that TSMC has already accumulated. The convergence of the hyperscaler custom silicon boom with the AI infrastructure buildout has created a demand environment for advanced TSMC capacity that is, as of mid-2025, still characterized by more demand than supply at the leading edge. TSMC faces a cluster of structural challenges that are as serious as any confronted by a company of its scale and strategic importance. A weak iPhone cycle, a delay in NVIDIA's next GPU generation, or a shift in hyperscaler AI investment timing could materially impact TSMC's near-term revenue trajectory. TSMC's competitive advantage is best understood not as a single moat but as a series of reinforcing barriers that have compounded over nearly four decades into something approaching structural invulnerability at the leading edge of semiconductor manufacturing. The first and most fundamental advantage is process technology leadership. The ecosystem advantage is equally powerful. Over thirty-five years, TSMC has built an ecosystem of equipment suppliers, materials providers, electronic design automation tools, and intellectual property vendors that is specifically optimized around TSMC's process libraries and design rules. This ecosystem lock-in means that switching to a competitor foundry would require not just technical qualification work but a fundamental redesign of internal development workflows, often representing years of engineering time. Trust and confidentiality represent a surprisingly critical competitive advantage in the foundry business. Finally, TSMC's manufacturing scale creates cost advantages that are self-reinforcing. This scale also gives TSMC preferential access to equipment from vendors like ASML — TSMC receives the largest allocation of EUV machines of any foundry customer globally, giving it first-mover advantage on each new equipment generation. Demand for advanced semiconductor manufacturing capacity is virtually certain to grow as AI inference workloads scale, autonomous vehicles become commercialized, and next-generation smartphones and personal computing devices deploy increasingly sophisticated silicon. Small companies with promising chip designs but limited capital had essentially no path to manufacturing their products at competitive scale.

Future prospects matter as much as current results. The growth strategies below explain how Novo Nordisk A/S and Taiwan Semiconductor Manufacturing Company each plan to expand from here.

Novo Nordisk A/S growth strategy: The introduction of Victoza (liraglutide) in 2009 marked the first shift toward incretin therapies, but it was the 2017 launch of Ozempic and the 2021 launch of Wegovy that triggered a paradigm shift in global medicine, transforming obesity from a lifestyle condition treated with behavioral counseling into a chronic neurological disease requiring lifelong pharmacological intervention. The remaining 26% of revenue is generated by legacy insulin analogs (Insulin glargine, Insulin aspart), growth hormone therapies, and hemophilia treatments, a portfolio that is growing at a low single-digit rate and serves primarily as a stable cash-flow baseline. To mitigate the risks associated with this extreme concentration, the business model incorporates aggressive inorganic growth and massive organic capital expenditure. The company uses its substantial free cash flow to acquire clinical-stage biotechnology companies and secure manufacturing capacity. This vertical integration strategy is designed to control the entire value chain, from the bacterial fermentation of the semaglutide peptide in Kalundborg, Denmark, to the final assembly of the FlexTouch injection pens in Hillerød, Denmark, and Clayton, North Carolina. This dynamic forces the company to maintain exceptionally high list prices to preserve its net revenue margins, a strategy that attracts intense political and regulatory scrutiny in the US and Europe. The ultimate goal of the business model is to achieve a sustainable compound annual growth rate (CAGR) of 15-20% at constant currency through 2030, a target that requires the successful launch of next-generation assets like CagriSema and oral amycretin, and the continuous expansion of manufacturing capacity to meet the estimated 1 billion obese patients globally who are candidates for pharmacological intervention. This logistical constraint creates a massive barrier to entry for competitors, as it requires the establishment of a decentralized network of specialized fill-finish facilities and cold-chain distribution partners, a capital-intensive infrastructure that Novo Nordisk has spent the last decade building through strategic acquisitions and organic investment. For Ozempic, the company has continuously expanded the label to include new indications such as cardiovascular risk reduction (based on the SELECT trial data) and chronic kidney disease, while also launching higher-dose formulations to improve glycemic control. The company's research centers in Bagsværd, Måløv, Oxford, and Cambridge focus on advanced areas such as oral peptide delivery, multi-receptor agonism, and gene editing. Novo Nordisk's response has been to pivot its diabetes portfolio toward combination therapies, such as the fixed-ratio combination of Insulin degludec and liraglutide (Xultophy), and to position its GLP-1 assets as the primary growth engine for the future. Novo Nordisk's competitive strategy in this space relies on continuous lifecycle management, launching new formulations and delivery methods to extend patent life and maintain premium pricing. To counter this, Novo Nordisk has adopted a 'buy and partner' strategy, using its massive balance sheet to acquire clinical-stage biotechs and secure exclusive rights to early-stage assets like Zealand Pharma's amycretin, effectively outsourcing the early-stage discovery risk to the private markets and then using its global commercial infrastructure to maximize the value of the assets. Novo Nordisk has responded by aggressively expanding its cardiovascular outcomes trial program, conducting the FLOW trial to evaluate the impact of semaglutide on chronic kidney disease, and the SELECT trial to evaluate its impact on major adverse cardiovascular events in non-diabetic obese patients. Selling, general, and administrative expenses were tightly controlled, growing at a slower rate than revenue, which contributed to the margin expansion. This capital return strategy is designed to support the stock price during the transition period between legacy insulin patents and new GLP-1 launches, signaling management's confidence in the long-term cash generation capabilities of the incretin-focused model. The FY2024 financial performance validates the strategic decision to pivot aggressively toward obesity therapeutics, as the removal of the low-margin legacy insulin focus has significantly improved the company's overall profitability metrics and return on invested capital. This substantial R&D investment is critical for maintaining the company's competitive position and driving future growth, and it is allocated across a diverse portfolio of early-stage discovery programs, Phase I and II clinical trials, and large-scale Phase III registrational studies like the SELECT and FLOW trials. Selling, general, and administrative (SG&A) expenses were 73.5 billion DKK, or 25.3% of net sales, reflecting the significant commercial investment required to launch and support the company's growing portfolio of GLP-1 therapies and navigate the complex PBM rebate landscape. The balance sheet at the end of FY2024 showed total assets of 412.5 billion DKK, total liabilities of 245.3 billion DKK, and total equity of 167.2 billion DKK, resulting in a debt-to-equity ratio of 0.65, which is well within the company's target range and provides a strong foundation for future growth and capital allocation initiatives. The implementation of the Inflation Reduction Act has enabled Medicare to negotiate drug prices, and while GLP-1s are currently excluded from the initial negotiation rounds due to their recent approval dates, the political momentum to include obesity therapies in future negotiations is growing rapidly. The commercial coverage of Wegovy for obesity is highly fragmented, with only a small percentage of commercial insurance plans and almost no Medicare plans covering the drug for weight loss alone, forcing Novo Nordisk to rely heavily on out-of-pocket payments and manufacturer copay cards, a strategy that is financially unsustainable in the long term. Finally, the company must manage the operational complexity of a massively expanded manufacturing footprint. Additionally, the company faces significant headwinds in the Chinese market, which has historically been a key driver of volume growth for its insulin portfolio. Novo Nordisk has responded by restructuring its commercial organization in China, shifting its focus toward a smaller portfolio of high-value innovative medicines like Ozempic, but the long-term impact of these regulatory pricing pressures on the company's growth trajectory in Asia remains a significant area of uncertainty for investors. The company's extensive experience in navigating the complex regulatory landscape for biologics, which involves coordination between multiple government agencies including the FDA, the EMA, and the WHO, provides it with a deep institutional knowledge base that accelerates the development and commercialization of new peptide assets. Novo Nordisk has invested billions of dollars in developing the FlexTouch and FlexTouch Plus injection devices, which are engineered to minimize injection site pain and ensure accurate dose delivery, a critical factor for patient compliance in chronic obesity treatment. Novo Nordisk A/S's growth strategy is built on three specific, named initiatives with clear financial targets: the acceleration of next-generation incretin therapy launches, the aggressive expansion of global manufacturing capacity through strategic acquisitions and organic investment, and the lifecycle management of key diabetes franchises. The company has committed to launching at least five new molecular entities or major label expansions between 2024 and 2030, a pipeline that includes potential blockbusters in obesity, diabetes, cardiovascular disease, and rare diseases. The incretin initiative is the cornerstone of this strategy, with the company investing heavily in clinical trials and manufacturing capacity to launch CagriSema, oral amycretin, and next-generation multi-receptor agonists. The manufacturing growth strategy focuses on eliminating the physical supply constraints that have limited Wegovy sales by executing a 28.6 billion DKK capital expenditure program to expand API and FDF capacity. The diabetes lifecycle management strategy aims to extend the commercial life of Insulin degludec and Insulin icodec by launching new combination therapies, such as fixed-ratio combinations with GLP-1 receptor agonists, and expanding into new indications like cardiovascular risk reduction. By continuously expanding the clinical utility of these assets, Novo Nordisk can defend against biosimilar competition and maintain premium pricing in key markets. To fund these initiatives, the company maintains a disciplined capital allocation framework that prioritizes R&D investment and targeted manufacturing acquisitions over large-scale, transformational mergers. The acquisition of Catalent and the partnership with Zealand Pharma exemplify this approach, providing the company with de-risked, late-stage assets and critical manufacturing capacity that can be integrated into the existing commercial infrastructure to drive immediate revenue growth. The execution of this growth strategy requires a highly skilled and motivated workforce, and Novo Nordisk has invested heavily in talent acquisition and development to ensure that it has the necessary scientific and commercial expertise to succeed. Novo Nordisk has also implemented a comprehensive training and development program for its employees, focusing on building the skills and capabilities required to succeed in the rapidly evolving pharmaceutical industry. The company's culture of innovation and collaboration is a key enabler of its growth strategy, fostering an environment where employees are encouraged to think creatively, take calculated risks, and work together to solve complex scientific and commercial challenges. The growth strategy also includes a strong focus on sustainability and corporate social responsibility, recognizing that the long-term success of the company is inextricably linked to the health and well-being of the communities in which it operates. Novo Nordisk has committed to achieving net zero greenhouse gas emissions across its value chain by 2030, and has implemented a comprehensive environmental, social, and governance (ESG) program that focuses on reducing its environmental footprint, promoting diversity and inclusion, and ensuring access to healthcare for underserved populations. The company's ESG initiatives are integrated into its overall business strategy, and its performance against these goals is regularly monitored and reported to stakeholders. The successful execution of Novo Nordisk's growth strategy will require the company to navigate a complex and dynamic external environment, characterized by rapid technological change, intense competition, and evolving regulatory and pricing pressures. However, the company's strong scientific heritage, strong pipeline, and disciplined capital allocation strategy provide a solid foundation for future growth, and its commitment to innovation and patient-centricity positions it well to deliver on its strategic objectives and create significant value for all stakeholders. The company projects a 15-20% constant currency sales CAGR from 2024 to 2030, a growth rate that relies heavily on the successful commercial launch of next-generation pipeline assets currently in Phase III trials. In the diabetes space, the launch of Insulin icodec (Awiqli), a once-weekly basal insulin, is expected to drive significant revenue growth and displace legacy daily insulin analogs, a therapeutic area where Novo Nordisk now holds a near-monopoly position in the weekly dosing category. Novo Nordisk has partnered with leading AI companies to identify novel peptide sequences and predict patient responses to therapy, a strategy that could significantly reduce the time and cost required to bring new drugs to market. In addition to GLP-1s, Novo Nordisk is heavily invested in the development of gene therapies and RNA-based therapeutics for rare bleeding disorders and rare endocrine diseases. The company's pipeline includes several gene therapy programs for hemophilia A and B, as well as a strong portfolio of siRNA therapeutics developed through its internal research and external partnerships. Novo Nordisk has invested heavily in its gene therapy manufacturing facilities in Denmark and the US, and has established a dedicated commercial team to support the launch of these complex therapies. The company is also exploring the use of digital biomarkers and wearable devices to collect real-time patient data during clinical trials, which could provide more sensitive and objective measures of drug efficacy and accelerate the regulatory approval process. The successful implementation of these digital health initiatives has the potential to significantly improve the productivity of the company's R&D organization and reduce the attrition rate of clinical candidates, ultimately leading to the faster and more efficient development of new medicines. The company faces intense competition in all of its key therapeutic areas, and the failure of any of its late-stage pipeline assets could have a material adverse impact on its financial performance and growth trajectory. Despite these challenges, Novo Nordisk's strong portfolio of innovative medicines, strong pipeline, and disciplined capital allocation strategy position it well to deliver sustained long-term growth and create significant value for its shareholders. Nordisk focused on purification and prolonged-action insulins, while Novo pioneered the use of recombinant DNA technology to produce human insulin. The early years of Novo Nordisk were marked by constant restructuring and a series of high-profile acquisitions designed to fill pipeline gaps, including the purchase of Genentech's insulin production rights and the expansion into hemophilia and growth hormone therapies.

Taiwan Semiconductor Manufacturing Company growth strategy: This is not market dominance in the conventional sense; it is something closer to a natural monopoly built on decades of compounding technical investment, workforce development, and manufacturing discipline. The economics are justified by the extraordinary capital expenditure required to build and operate leading-edge fabs. Advanced packaging is expected to grow as a proportion of TSMC revenue as chiplet architectures — designs that disaggregate semiconductor functions across multiple dies — become the dominant approach to pushing past the physical limits of conventional scaling. TSMC's Arizona fabs, its Kumamoto, Japan fab (producing 28-nanometer to 12-nanometer chips in partnership with Sony and Denso), and its Nanjing, China facility together represent less than 10 percent of total wafer capacity as of 2024. Once a fab is built and a process is qualified, the marginal cost of additional wafers is significantly lower than the average cost, enabling gross margins to expand as use rates improve. The structure effectively turns some of TSMC's capital expenditure risk into shared investment with customers who have strategic reasons to ensure TSMC's manufacturing capacity remains available to them. Intel's foundry ambitions were articulated as a core element of the IDM 2.0 strategy — Intel Design and Manufacture, integrating internal chip design with external foundry services. Money can accelerate progress; it cannot buy thirty-five years of compounded manufacturing learning. This is theoretically possible but practically prohibitive: building and operating a leading-edge fab requires not just capital but a generation of accumulated manufacturing knowledge that even trillion-dollar companies cannot shortcut. The competitive dynamics are also being reshaped by the AI investment cycle in ways that benefit TSMC more than any other participant. NVIDIA's dominance of AI GPU markets has made TSMC its exclusive manufacturing partner, and the extraordinary economics of AI infrastructure — where a single H100 GPU commands $25,000 to $40,000 at retail while costing TSMC perhaps $3,000 to $5,000 in wafer costs — generate compelling economics across the supply chain. Moving from 3-nanometer to 2-nanometer to 1.4-nanometer processes requires not just incremental investment but generational leaps in equipment sophistication and process complexity. TSMC's growth strategy rests on three pillars that have remained remarkably consistent across management transitions and business cycles. The first is relentless process technology leadership: investing ahead of demand to ensure that when customers need the next generation of manufacturing capability, TSMC is the only credible option. The company's roadmap through 2-nanometer, A16, and eventually 1-nanometer-class processes (internally designated N1) represents a manufacturing technology pipeline that should sustain TSMC's leading-edge premium for at least the next decade. This government partnership model allows TSMC to expand geographic footprint without bearing the full incremental cost burden of manufacturing in higher-cost geographies. The third pillar is advanced packaging technology as a growth vector in its own right. Advanced packaging capacity expansion represented a major strategic investment in 2024 and 2025, with TSMC building dedicated packaging facilities in Taiwan to address the CoWoS bottleneck that constrained NVIDIA GPU shipments through 2023 and much of 2024. The key growth driver remains AI infrastructure: NVIDIA's Blackwell GPU architecture (manufactured at TSMC's 4-nanometer node), Apple's continued advancement of its silicon roadmap, and the proliferation of custom AI silicon across the hyperscaler community all point toward sustained strong demand for TSMC's most advanced manufacturing capacity through at least 2027. He spent a brief and reportedly unsatisfying period at General Instrument before receiving a call that would define his legacy: an offer to lead the Industrial Technology Research Institute (ITRI) in Taiwan, and to develop a strategy for building a semiconductor industry on the island. They either partnered with large integrated companies, which often meant giving up strategic control, or they struggled to raise enough capital to build their own factories, which distracted from the core engineering work of designing better chips. In exchange, customers would access world-class manufacturing without the capital burden of building their own fabs. The Philips partnership was particularly critical — it gave TSMC access to CMOS process technology that would have taken years to develop independently and provided a degree of international legitimacy that helped attract the company's first external customers. The earliest days were marked by the unglamorous work of building manufacturing capability from scratch. TSMC's first fab, Fab 1 in Hsinchu, was a converted building that produced chips on 6-inch wafers using 2-micron process technology — sophisticated by the standards of 1987 Taiwan but not at the absolute frontier. The company's first major external customer was a small American chip design company that needed manufacturing capacity it could not afford to build internally.

A closer look at the financial trajectory of Novo Nordisk A/S and Taiwan Semiconductor Manufacturing Company rounds out the comparison.

Novo Nordisk A/S: Revenue grew from $24.8 billion in FY2022 to $33.4 billion in FY2023 to $42.7 billion in FY2024 — a two-year compound growth rate of approximately 31% that is, for a company of this size, essentially without precedent in pharmaceutical history. Operating profit reached 125.3 billion DKK in FY2024, with an operating margin of 43.1%. Free cash flow of 91.2 billion DKK was deployed partially into the record 28.6 billion DKK capital expenditure program to expand manufacturing capacity. The semaglutide franchise breakdown illustrates the market's composition: Ozempic (diabetes indication) generated 146.9 billion DKK, Wegovy (obesity indication) generated 68.2 billion DKK. The obesity market is structurally larger than the diabetes market in terms of addressable population, and Wegovy's growth rate in FY2024 significantly exceeded Ozempic's — suggesting that the revenue mix will continue shifting toward obesity over the medium term as manufacturing constraints ease and insurance coverage expands. The capital expenditure program of 28.6 billion DKK in FY2024 — the largest in European pharmaceutical history — reflects the magnitude of the capacity constraint. Novo Nordisk's active pharmaceutical ingredient production and sterile fill-finish capabilities cannot scale quickly; the regulatory requirements for pharmaceutical manufacturing mean that new capacity requires years of construction and validation before it can produce commercial product. Novo Holdings' acquisition of Catalent was intended to accelerate that timeline by acquiring existing validated facilities rather than building from scratch. The $550 billion market capitalization at fiscal year-end made Novo Nordisk the most valuable company in Europe by a significant margin, representing approximately 12.9x FY2024 revenue. That multiple prices in continued semaglutide dominance, successful next-generation product launches, and the expansion of GLP-1 indications beyond diabetes and obesity into cardiovascular disease, chronic kidney disease, and potentially other metabolic conditions.

Taiwan Semiconductor Manufacturing Company: TSMC earned $35 billion in net income on $90 billion in fiscal 2024 revenue — a 38.9% net margin that is extraordinary for any manufacturing company and that reflects genuine pricing power rather than accounting artifact. Gross margins ran at 53-54% in the second half of 2024. A company with $90 billion in revenue and a 39% net margin is generating earnings that most software companies with ten times the revenue cannot match. Revenue growth has been dramatic: $57.7 billion in fiscal 2021, $75.9 billion in fiscal 2022, a decline to $67.6 billion in fiscal 2023 as semiconductor demand corrected from pandemic-era overordering, and then $90 billion in fiscal 2024 as AI chip demand overwhelmed the correction. The $22.4 billion single-year increase from fiscal 2023 to fiscal 2024 is larger than the total annual revenue of most semiconductor companies. The Arizona fab investment has expanded from the initial $12 billion announcement to over $65 billion — the largest single manufacturing investment in American history. That capital commitment has been driven by US government incentives under the CHIPS Act and by customer pressure from Apple, NVIDIA, and AMD to maintain a manufacturing presence in the United States as a hedge against Taiwan-related supply disruption. The per-wafer cost at Arizona fabs will initially be higher than Taiwan operations, but TSMC has demonstrated that it can close cost gaps over time as yields improve and operations mature. The $900 billion market capitalization places TSMC at ten times fiscal 2024 revenue. That valuation has a specific basis: the company manufactures something that no other entity can manufacture at comparable volume, quality, or process sophistication, and demand for that something is growing faster than TSMC can build capacity. The geopolitical discount — which markets apply to the Taiwan concentration risk — is offset by the AI demand premium, producing a net valuation that reflects both the opportunity and the risk simultaneously.